Catalent Balance Sheet Health

Financial Health criteria checks 1/6

Catalent has a total shareholder equity of $3.5B and total debt of $4.6B, which brings its debt-to-equity ratio to 130%. Its total assets and total liabilities are $9.7B and $6.2B respectively.

Key information

130.0%

Debt to equity ratio

US$4.61b

Debt

Interest coverage ration/a
CashUS$335.00m
EquityUS$3.54b
Total liabilitiesUS$6.17b
Total assetsUS$9.71b

Recent financial health updates

Recent updates

Catalent, Inc.'s (NYSE:CTLT) Share Price Not Quite Adding Up

Aug 30
Catalent, Inc.'s (NYSE:CTLT) Share Price Not Quite Adding Up

Are Investors Undervaluing Catalent, Inc. (NYSE:CTLT) By 24%?

Jul 23
Are Investors Undervaluing Catalent, Inc. (NYSE:CTLT) By 24%?

Beyond Elevidys: Unveiling The Competitive Landscape Of Duchenne's Muscular Dystrophy

Jun 25

Catalent - Novo Holdings Merger: Attractive Spread

Feb 07

Catalent: Debt Remains An Overhang

Dec 13

Catalent Remains Overvalued

Oct 04

Calculating The Intrinsic Value Of Catalent, Inc. (NYSE:CTLT)

Aug 14
Calculating The Intrinsic Value Of Catalent, Inc. (NYSE:CTLT)

Catalent: Myriad Issues To Fix

Jul 31

Catalent (NYSE:CTLT) Has A Somewhat Strained Balance Sheet

May 05
Catalent (NYSE:CTLT) Has A Somewhat Strained Balance Sheet

A Look At The Intrinsic Value Of Catalent, Inc. (NYSE:CTLT)

Mar 27
A Look At The Intrinsic Value Of Catalent, Inc. (NYSE:CTLT)

Why did Catalent stock soar today? Potential takeover by Danaher

Feb 06

We Think Catalent (NYSE:CTLT) Is Taking Some Risk With Its Debt

Feb 01
We Think Catalent (NYSE:CTLT) Is Taking Some Risk With Its Debt

Catalent to make Sarepta Therapeutics' muscle wasting gene therapy under supply deal

Jan 05

An Intrinsic Calculation For Catalent, Inc. (NYSE:CTLT) Suggests It's 27% Undervalued

Dec 27
An Intrinsic Calculation For Catalent, Inc. (NYSE:CTLT) Suggests It's 27% Undervalued

Humanigen to pay Catalent Pharma $12M to settle supply agreement dispute

Dec 22

Catalent falls after new short call from Glasshouse Research

Dec 08

Catalent Q1 2023 Earnings Preview

Oct 31

These 4 Measures Indicate That Catalent (NYSE:CTLT) Is Using Debt Extensively

Oct 26
These 4 Measures Indicate That Catalent (NYSE:CTLT) Is Using Debt Extensively

Catalent: Charting A Post-Covid Future

Oct 19

Financial Position Analysis

Short Term Liabilities: CTLT's short term assets ($2.5B) exceed its short term liabilities ($998.0M).

Long Term Liabilities: CTLT's short term assets ($2.5B) do not cover its long term liabilities ($5.2B).


Debt to Equity History and Analysis

Debt Level: CTLT's net debt to equity ratio (120.6%) is considered high.

Reducing Debt: CTLT's debt to equity ratio has increased from 122.6% to 130% over the past 5 years.

Debt Coverage: CTLT's debt is not well covered by operating cash flow (8.7%).

Interest Coverage: Insufficient data to determine if CTLT's interest payments on its debt are well covered by EBIT.


Balance Sheet


Discover healthy companies